MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
1.440
+0.070
+5.11%
After Hours: 1.390 -0.05 -3.47% 16:36 12/24 EST
OPEN
1.370
PREV CLOSE
1.370
HIGH
1.480
LOW
1.370
VOLUME
217.19K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.090
MARKET CAP
14.52M
P/E (TTM)
-0.3935
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNGX last week (1215-1219)?
Weekly Report · 3d ago
Alliance Global Partners Sticks to Its Buy Rating for Soligenix (SNGX)
TipRanks · 6d ago
Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)
TipRanks · 12/18 12:41
Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)
Benzinga · 12/18 12:35
Soligenix Reports Positive Phase 2 Results for SGX945 in Behçet's Disease
Reuters · 12/18 12:30
SOLIGENIX INC - SGX945 WELL-TOLERATED WITH NO TREATMENT-RELATED ADVERSE EVENTS
Reuters · 12/18 12:30
POSITIVE CLINICAL RESULTS FROM PHASE 2 TRIAL OF SGX945 FOR THE TREATMENT OF BEHÇET'S DISEASE PUBLISHED IN RHEUMATOLOGY (OXFORD)
Reuters · 12/18 12:30
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
Benzinga · 12/17 18:23
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.